Drug treatment of chronic heart failure in the elderly

Drugs and Aging

Volumn 24, Issue 12, 2007, Pages 991-1006

  Leibundgut, Gregor ^a   Pfisterer, Matthias ^a   Brunner La Rocca, Hans Peter ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

ACE inhibitors, therapeutic use; Aldosterone antagonists, therapeutic use; Angiotensin receptor antagonists, therapeutic use; Beta adrenergic receptor antagonists, therapeutic use; Bisoprolol, therapeutic use; Candesartan cilexetil, therapeutic use

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; FELODIPINE; FUROSEMIDE; HYDRALAZINE; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; METOPROLOL; METOPROLOL SUCCINATE; NEBIVOLOL; NITRATE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN; VASODILATOR AGENT;

AGE DISTRIBUTION; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL; COMORBIDITY; DEFIBRILLATOR; DISEASE EXACERBATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELDERLY CARE; GYNECOMASTIA; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; LIFE EXPECTANCY; LOW DRUG DOSE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QRS COMPLEX; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 36348937791     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724120-00003     Document Type: Review

References (102)

1. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-40
2. Puggaard L. Age-related decline in maximal oxygen capacity: consequences for performance of everyday activities. J Am Geriatr Soc 2005; 53: 546-7
3. Morgan S, Smith H, Simpson I, et al. Prevalence and clinical characteristics of left ventricular dysfunction among elderly patients in general practice setting: cross sectional survey. BMJ 1999; 318: 368-72
4. Wang CS, FitzGerald JM, Schulzer M, et al. Does this dyspneic patient in the emergency department have congestive heart failure? JAMA 2005; 294: 1944-56
5. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154-235
6. Muntwyler J, Abetel G, Gruner C, et al. One-year mortality among unselected outpatients with heart failure. Eur Heart J 2002; 23: 1861-6
7. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics: 2006 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: e85-151
8. Kupari M, Lindroos M, Iivanainen AM, et al. Congestive heart failure in old age: prevalence, mechanisms and 4-year prognosis in the Helsinki Ageing Study. J Intern Med 1997; 241: 387-94
9. Masoudi FA, Havranek EP, Krumholz HM. The burden of chronic congestive heart failure in older persons: magnitude and implications for policy and research. Heart Fail Rev 2002; 7: 9-16
10. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 1997; 133: 703-12
11. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 2002; 162: 1682-8
12. Lien CT, Gillespie ND, Struthers AD, et al. Heart failure in frail elderly patients: diagnostic difficulties, co-morbidities, polypharmacy and treatment dilemmas. Eur J Heart Fail 2002; 4: 91-8
13. MacIntyre K, Capewell S, Stewart S, et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation 2000; 102: 1126-31
14. Jong P, Vowinckel E, Liu PP, et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med 2002; 162: 1689-94
15. Ponikowski P, Piepoli M, Chua TP, et al. The impact of cachexia on cardiorespiratory reflex control in chronic heart failure. Eur Heart J 1999; 20: 1667-75
16. Pekkanen J, Nissinen A, Vartiainen E, et al. Changes in serum cholesterol level and mortality: a 30-year follow-up. The Finnish cohorts of the Seven Countries Study. Am J Epidemiol 1994; 139: 155-65
17. Bulpitt CJ. Secondary prevention of coronary heart disease in the elderly. Heart 2005; 91: 396-400
18. Cheitlin MD. Cardiovascular physiology: changes with aging. Am J Geriatr Cardiol 2003; 12: 9-13
19. Bozkurt B, Deswal A. Obesity as a prognostic factor in chronic symptomatic heart failure. Am Heart J 2005; 150: 1233-9
20. Zuccala G, Onder G, Pedone C, et al. Hypotension and cognitive impairment: selective association in patients with heart failure. Neurology 2001; 57: 1986-92
21. McGann PE. Comorbidity in heart failure in the elderly. Clin Geriatr Med 2000; 16: 631-48
22. Williamson J, Chopin JM. Adverse reactions to prescribed drugs in the elderly: a multicentre investigation. Age Ageing 1980; 9: 73-80
23. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004; 43: 317-27
24. Masoudi FA, Havranek EP, Smith G, et al. Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2003; 41: 217-23
25. Adhiyaman V, Asghar M, Oke A, et al. Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs. J R Soc Med 2001; 94: 512-4
26. McAlister FA, Stewart S, Ferrua S, et al. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 2004; 44: 810-9
27. Brunner-La Rocca HP, Buser PT, Schindler R, et al. Management of elderly patients with congestive heart failure: design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J 2006; 151: 949-55
28. Amabile CM, Spencer AP. Keeping your patient with heart failure safe: a review of potentially dangerous medications. Arch Intern Med 2004; 164: 709-20
29. Burgess CL, Holman CD, Satti AG. Adverse drug reactions in older Australians, 1981-2002. Med J Aust 2005; 182: 267-70
30. Turnheim K. Drug therapy in the elderly. Exp Gerontol 2004; 39: 1731-8
31. Shibata MC, Soneff CM, Tsuyuki RT. Utilization of evidence-based therapies for heart failure in the institutionalized elderly. Eur J Heart Fail 2005; 7: 1122-5
32. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-66
33. Baracskay D, Jarjoura D, Cugino A, et al. Geriatric renal function: estimating glomerular filtration in an ambulatory elderly population. Clin Nephrol 1997; 47: 222-8
34. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
35. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70
36. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-47
37. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-9
38. Bursi F, Weston SA, Redfield MM, et al. Systolic and diastolic heart failure in the community. JAMA 2006; 296: 2209-16
39. Fonarow GC, Yancy CW, Heywood JT. Adherence to heart failure quality-of-care indicators in US hospitals: analysis of the ADHERE Registry. Arch Intern Med 2005; 165: 1469-77
40. Feinglass J, Martin GJ, Lin E, et al. Is heart failure survival improving? Evidence from 2323 elderly patients hospitalized symptobetween 1989 and 2000. Am Heart J 2003; 146: 111-4
41. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-51
42. Ahmed A, Husain A, Love TE, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 2006; 27: 1431-9
43. van Kraaij DJ, Jansen RW, Sweep FC, et al. Neurohormonal effects of furosemide withdrawal in elderly heart failure patients with normal systolic function. Eur J Heart Fail 2003; 5: 47-53
44. Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4: 507-13
45. Lopez B, Querejeta R, Gonzalez A, et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43: 2028-35
46. Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005; 112: 2426-35
47. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure: Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-6
48. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575-81
49. Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am J Med 2002; 113: 650-6
50. Havranek EP, Abrams F, Stevens E, et al. Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors. Arch Intern Med 1998; 158: 2024-8
51. Pulignano G, Del Sindaco D, Tavazzi L, et al. Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). Am Heart J 2002; 143: 45-55
52. Greenbaum R, Zucchelli P, Caspi A, et al. Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal Disinsufficiency. Br J Clin Pharmacol 2000; 49: 23-31
53. Hoyer J, Schulte KL, Lenz T. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure. Clin Pharmacokinet 1993; 24: 230-54
54. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-6
55. Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002; 40: 1414-21
56. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-7
57. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-906
58. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75
59. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-71
60. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-8
61. Goldstein S, Fagerberg B, Hjalmarson A, et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J Am Coll Cardiol 2001; 38: 932-8
62. Erdmann E, Lechat P, Verkenne P, et al. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001; 3: 469-79
63. Deedwania PC, Gottlieb S, Ghali JK, et al. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J 2004; 25: 1300-9
64. Wikstrand J, Wedel H, Ghali J, et al. How should subgroup analyses affect clinical practice? Insights from the Metoprolol Succinate Controlled-Release/ Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Card Electrophysiol Rev 2003; 7: 264-75
65. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-25
66. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-55
67. McMurray J. Making sense of SENIORS. Eur Heart J 2005; 26: 203-6
68. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13
69. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7
70. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13
71. Coca SG, Buller GK. COMET: a proposed mechanism of action to explain the results and concerns about dose [letter]. Lancet 2003; 362: 1076
72. Wikstrand J, Fagerberg B, Goldstein S, et al. COMET: a proposed mechanism of action to explain the results and concerns about dose [letter]. Lancet 2003; 362: 1076
73. Hjalmarson A, Waagstein F. COMET: a proposed mechanism of action to explain the results and concerns about dose [letter]. Lancet 2003; 362: 1077
74. Poole-Wilson PA, Swedberg K, Cleland JG, et al. COMET: a proposed mechanism of action to explain the results and concerns about dose [letter]. Lancet 2003; 362: 1077
75. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17
76. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21
77. DIG. The effect of digoxin on mortality and morbidity in patients with heart failure: the Digitalis Investigation Group. N Engl J Med 1997; 336: 525-33
78. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006; 27: 178-86
79. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351: 2049-57
80. Elkayam U, Johnson JV, Shotan A, et al. Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with chronic heart failure treated with angiotensin-converting enzyme inhibition. Circulation 1999; 99: 2652-7
81. Katz S. Safety of calcium antagonists in patients with congestive heart failure. Clin Ther 1997; 19 Suppl. A: 92-113
82. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure: Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335: 1107-14
83. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-trophysiol HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997; 96: 856-63
84. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-49
85. Cleland JG, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure (the CArdiac REsynchronization-Heart Failure [CARE-HF] trial extension phase). Eur Heart J 2006; 27: 1928-32
86. Calvert MJ, Freemantle N, Yao G, et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur Heart J 2005; 26: 2681-8
87. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-37
88. Nanthakumar K, Epstein AE, Kay GN, et al. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 2004; 44: 2166-72
89. Healey JS, Hallstrom AP, Kuck KH, et al. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. Eur Heart J 2007; 28: 1746-9
90. Grimm W, Stula A, Sharkova J, et al. Outcomes of elderly recipients of implantable cardioverter defibrillators. Pacing Clin Electrophysiol 2007; 30 Suppl. 1: S134-8
91. Kitzman DW. Diastolic heart failure in the elderly. Heart Fail Rev 2002; 7: 17-27
92. Banerjee P, Clark AL, Cleland JG. Diastolic heart failure: a difficult problem in the elderly. Am J Geriatr Cardiol 2004; 13: 16-21
93. Regitz-Zagrosek V, Brokat S, Tschope C. Role of gender in heart failure with normal left ventricular ejection fraction. Prog Cardiovasc Dis 2007; 49: 241-51
94. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-81
95. Cleland JG, Tendera M, Adamus J, et al. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338-45
96. Bergstrom A, Andersson B, Edner M, et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function: results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004; 6: 453-61
97. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ≥40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol 1997; 80: 207-9
98. Arques S, Ambrosi P, Gelisse R, et al. Prevalence of angiographic coronary artery disease in patients hospitalized for acute diastolic heart failure without clinical and electrocardiographic evidence of myocardial ischemia on admission. Am Cardiol 2004; 94: 133-5
99. Casarett D, Van Ness PH, O'Leary JR, et al. Are patient preferences for life-sustaining treatment really a barrier hospice enrollment for older adults with serious illness? J Am Geriatr Soc 2006; 54: 472-8
100. Pullicino PM, Hart J. Cognitive impairment in congestive heart failure? Embolism vs hypoperfusion. Neurology 2001; 57: 1945-6
101. Zuccala G, Onder G, Marzetti E, et al. Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. Eur Heart J 2005; 26: 226-33
102. Brunner-La Rocca HP, Capraro J, Kiowsk W. Compliance by referring physicians with recommendations on heart failure therapy from a tertiary center. J Cardiovasc Pharmacol Ther 2006; 11: 85-92